The US Department of Health and Human Services (HHS) announced a $500 million initiative to develop universal flu and coronavirus vaccines within four years. This project, using inactivated whole-virus technology, aims for FDA approval by 2029. While experts praise the goal, some question the use of older technology and the potential for adverse reactions. Concurrently, HHS announced new, stricter safety testing requirements for updated COVID-19 vaccines, potentially delaying their availability. This change has raised concerns amongst experts and Congress.

Prepared by Olivia Bennett and reviewed by editorial team.